Featured Radiology Articles on HCP
Spinal Muscular Atrophy: June Bi-Monthly Roundup

Spinal Muscular Atrophy: June Bi-Monthly Roundup

Since our last roundup, there has been continued focus in the spinal muscular atrophy (SMA) literature how best to treat the disease. There also continues to be research geared toward understanding the biology of the disease, as well as on SMA management, what it is...

Spinal Muscular Atrophy: Monthly Roundup

Spinal Muscular Atrophy: Monthly Roundup

Much of the most recent research regarding spinal muscular atrophy (SMA) has focused on understanding the mechanisms mediating the disease as well as the clinical value of different pharmaceutical interventions. There have been several reviews on the latter topic,...

FDA Approves AveXis’ Gene Therapy Zolgensma to Treat SMA in Children Up to Age 2

FDA Approves AveXis’ Gene Therapy Zolgensma to Treat SMA in Children Up to Age 2

Zolgensma, a first gene therapy for spinal muscular atrophy — and first for any chronic neurologic disease — is now an approved and potential “one-time” intravenous treatment for pre-symptomatic newborns through 2-year-olds with any type of SMA, the U.S. Food and Drug...

The Common Cold, Antibiotics and SMA

The Common Cold, Antibiotics and SMA

Our experience with SMA is a unique one. As parents of a 9 year-old with SMA, being medical professionals has given us somewhat of an advantage over finding doctors, medications, and treatments for our son. We hope to share a little of our experience and opinion with...

Radiology Related SMA Resources

Latest Posts from SMA News Today

Recent SMA Radiologist News

RSS feed from SMA News Today

Radiology Related Forum Topics

RSS feed from SMA News Today

Subscribe to our mailing list

* indicates required
Privacy Policy
Email Format
Please select all the ways you would like to hear from BioNews Services, LLC:
You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.
We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.